Preferred Label : Generalized epilepsy with febrile seizures plus, type 2;
Symbol : GEFSP2;
CISMeF acronym : FEB3A; GEFSP2; GEFS 2;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Gefs , type 2; GEFS 2;
Included titles and symbols : Febrile seizures, familial, 3a; FEB3A;
Description : Mutations in the SCN1A gene cause a spectrum of seizure disorders, ranging from early-onset
isolated febrile seizures to generalized epilepsy with febrile seizures plus, type
2, which represents a more severe phenotype. Patients with isolated febrile seizures
usually have onset between ages 6 months and 4 years and show spontaneous remission
by age 6 years (summary by Mantegazza et al., 2005), whereas patients with GEFS continue
to have various types of febrile and afebrile seizures later in life (summary by Singh
et al., 2009). Dravet syndrome (607208), or severe myoclonic epilepsy of infancy,
is the most severe phenotype associated with SCN1A mutations. Mutations in certain
genes can cause a phenotypic spectrum of overlap between the isolated febrile phenotype
and the GEFS phenotype. For a general phenotypic description and a discussion of
genetic heterogeneity of GEFS , see 604233. For a phenotypic description and a discussion
of genetic heterogeneity of familial febrile seizures, see 121210.;
Inheritance : Autosomal dominant;
Molecular basis : Caused by mutation in the voltage-gated sodium channel type I, alpha polypeptide gene
(SCN1A, 182389.0001);
Prefixed ID : #604403;
Origin ID : 604403;
UMLS CUI : C1858673;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT